This biotech company develops a platform that utilizes artificial intelligence, computer vision, and high-content screening to analyze tumor stroma in complex disease models. By enabling pharmaceutical companies to identify drug candidates more efficiently, the platform addresses the challenges of drug discovery in oncology.
Funding
$8.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Outcomes for patients with solid tumors remain poor because current drug discovery methods often fail to account for the diversity of cell types and interactions within human tumors. Traditional drug development relies on models that do not fully represent the complexity of the tumor microenvironment, leading to ineffective clinical translation.
Solution
Phenomic AI offers a machine learning-powered transcriptomics platform that analyzes single-cell data from human tissues to understand cell-type interactions within solid tumors. The platform identifies compelling drug targets and tests drug candidates in human tumor explants, providing translational insights during the discovery process. By exploring cell type and target expression profiles in detail, Phenomic AI aims to unlock new therapeutic approaches that address the limitations of traditional tumor-associated antigens. The company's lead program is a CD3 engager that uses a novel targeting approach to overcome these limitations, demonstrating the platform's ability to identify high-impact, druggable targets.
Target Audience
The primary customers are pharmaceutical companies seeking to identify and validate novel drug targets for stroma-rich cancers, as well as research institutions focused on advancing cancer therapeutics.
Features
- scTx® single-cell transcriptomics platform for high-resolution analysis of the tumor microenvironment
- Machine learning algorithms for processing imaging, RNA sequencing, and spatial transcriptomics data
- Target identification and validation using in vitro and in vivo assays
- Capability to analyze cell type and target expression profiles in human cancer and normal tissue samples
- Identification of novel targets to develop first-in-class therapies that target the tumor stroma
- Internal drug candidate development focused on CTHRC1, a gene associated with solid tumors